Latest Headlines

PR Newswire

Frontier Biotech et GSK concluent un accord de licence exclusif à l'échelle mondiale pour les thérapies fondées sur les petits ARN interférents (siRNA)

PR Newswire

PARAMOUNT COMMENTS ON WARNER BROS. DISCOVERY BOARD'S DETERMINATION THAT PARAMOUNT PROPOSAL COULD REASONABLY BE EXPECTED TO LEAD TO A SUPERIOR PROPOSAL

PR Newswire

Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)